Charles, Pierre <br/><br/>
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).  [electronic resource] 

 -  Annals of the rheumatic diseases  08 2018 
 - 1143-1149 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1468-2060 
<br/><br/><label>Standard No.: </label>10.1136/annrheumdis-2017-212878  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis--drug therapy<br/>Antibodies, Antineutrophil Cytoplasmic--blood<br/>Antirheumatic Agents--administration & dosage<br/>B-Lymphocyte Subsets--drug effects<br/>Biomarkers--blood<br/>Drug Administration Schedule<br/>Drug Monitoring--methods<br/>Female<br/>Humans<br/>Infusions, Intravenous<br/>Kaplan-Meier Estimate<br/>Lymphocyte Count<br/>Male<br/>Middle Aged<br/>Precision Medicine--methods<br/>Recurrence<br/>Remission Induction--methods<br/>Rituximab--administration & dosage<br/>Severity of Illness Index